Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig in Localized Prostate Cancer
NCT07860255Phase 1Not yet recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pasritamig in prostate cancer (PCa), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Feasibility of neoadjuvant pasritamig at 70 days and Change in intratumoral CD3+ T-cell density at 70 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pasritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07860255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07860255.